Teva Announces Favorable Court Ruling in Generic Hyzaar(R) and Cozaar(R
MarketWatch (press release)
Lotrel(R), Protonix(R) and Eloxatin(R), the current economic conditions, competition from brand-name companies that are under increased pressure to

and more »

TopNews New Zealand
Teva Reports Record Full Year 2009 and Fourth Quarter Results
MarketWatch (press release)
Lotrel(R), Protonix(R) and Eloxatin(R), the current economic conditions, competition from brand-name companies that are under increased pressure to
Teva Pharmaceutical Industries announces fourth-quarter and full-year 2009 News-Medical.net

all 255 news articles »

Pneumonia death in healthy young people is rare
Herald & Review
Prilosec, Protonix, Aciphex and Nexium are their brand names. People who take these drugs for prolonged periods and in high doses run a greater risk of

and more »

Copaxone(R) 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust
MarketWatch (press release)
Lotrel(R), Protonix(R) and Eloxatin(R), the current economic conditions, competition from brand-name companies that are under increased pressure to

and more »

Pneumonia death in healthy young people is rare
Herald & Review
Prilosec, Protonix, Aciphex and Nexium are their brand names. People who take these drugs for prolonged periods and in high doses run a greater risk of

and more »

Procedure at Los Robles Hospital the first for Ventura County
Thousand Oaks Acorn
“Treating GERD with medications such as H2-blockers like Pepcid, Zantac, Axid, etc., or proton pump inhibitors like Prilosec, Nexium, Protonix, etc.,

and more »

TopNews New Zealand
Teva Reports Record Full Year 2009 and Fourth Quarter Results
MarketWatch (press release)
Since the beginning of 2009, Teva received 1035 generic approvals in Europe relating to 164 compounds in 324 formulations, including 12 European Commission
Teva sales soar again as new generic launches drive growthPharma Times
Teva Just Misses, But Revenues RiseSeeking Alpha (blog)

all 255 news articles »

Copaxone(R) 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust
MarketWatch (press release)
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic

and more »

Copaxone(R) 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust
MarketWatch (press release)
The most common side effects of Copaxone(R) are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath,

and more »

Weekly gains for Sensex after a month
India Infoline.com
According to a report released by IIFL during the week, “With most of the potential bad news in the price, we do not expect any significant de-rating for

and more »

Teva Reports Record Full Year 2009 and Fourth Quarter Results
MarketWatch (press release)
(a) Cost of Sales includes $124 million and $35 million of amortization of purchased intangible assets in the three months ended December 31, 2009 and 2008,

and more »